WO2008075455A1 - トロンビン含有溶液中のα-トロンビンの安定化方法 - Google Patents
トロンビン含有溶液中のα-トロンビンの安定化方法 Download PDFInfo
- Publication number
- WO2008075455A1 WO2008075455A1 PCT/JP2007/001367 JP2007001367W WO2008075455A1 WO 2008075455 A1 WO2008075455 A1 WO 2008075455A1 JP 2007001367 W JP2007001367 W JP 2007001367W WO 2008075455 A1 WO2008075455 A1 WO 2008075455A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- thrombin
- containing solution
- solution
- activity
- content
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
Definitions
- the present invention relates to a method for stabilizing an unstable thrombin in a thrombin-containing solution.
- the present invention relates to a thrombin-containing solution in which one thrombin is stabilized, and a liquid fibrinogen measurement reagent containing the same.
- Fibrinogen is a precursor of fibrin, the main protein of blood clots, and is produced in hepatocytes. About 80% of fibrinogen in the living body is distributed in plasma (about 20 to 40 Omg / dL in healthy adults), and the rest is distributed in tissues. Fibrinogen is a glycoprotein containing three pairs of polypeptide chains (A, ⁇ , and r) linked by disulfide. A and B; the three chains are degraded by thrombin to become fibrin. It plays a major role in thrombus formation and hemostatic thrombus. Clinically, it increases with inflammation, and decreases with advanced liver dysfunction and DIC.
- Methods for measuring fibrinogen include the Claus method (thrombin addition method), PT deri Ved method (coagulation time method), TIA (immunoturbidimetry) method, latex method, etc.
- the thrombin addition method That is, add thrombin and calcium chloride to a plasma sample of citrate Na, measure the coagulation time, and calculate the fibrinogen concentration (mg / dL) of the sample from a calibration curve prepared using fibrinogen of known concentration. A method of obtaining by calculation is performed.
- Thrombin used for fibrinogen measurement is a thrombin having a clotting activity by cutting a peptide from its precursor, prothrombin.
- This a-thrombin has no low molecular weight clotting activity; S_thrombin, and also: ⁇ _thrombin is known to cause autolysis and is usually lyophilized for long-term storage. It was.
- Patent Document 3 As a method for stabilizing thrombin in a fibrinogen measurement reagent, a method of adding a thrombin antagonist to a thrombin-containing solution (Patent Document 3) is known.
- This method is based on inhibiting the activity of thrombin. For this reason, when this method is used, the clotting time is extremely delayed for fibrinogen low-concentration specimens that have important measurement significance in fibrinogen measurement tests, and in some cases, measurement is impossible. This not only reduces the number of specimens processed per hour but also increases the number of retests due to the inability to measure low fibrinogen concentrations, making this method unsuitable for emergency testing.
- Patent Document 1 JP-A-62-106028
- Patent Document 2 JP-A 64-040433
- Patent Document 3 JP 2004 _ 1 91 367
- An object of the present invention is to provide a method for stabilizing an unstable one-thrombin in a thrombin-containing solution, a thrombin-containing solution in which one thrombin is stabilized, and a liquid fibrinogen measurement reagent containing the same. is there.
- ⁇ -thrombin and r_toro Nimbin was only thought to be an autolysis product of a single thrombin, but ⁇ - and -thrombin has a degrading activity that acts on a single thrombin rather than a self-degradation that acts on a single thrombin. I found something stronger. And, by suppressing the content of S- and / or r-thrombin to a certain range with respect to the total thrombin, it was surprisingly unexpected that one thrombin, which was previously considered unstable due to autolysis, The present invention was completed by finding that it can be stabilized in a solution.
- the present invention provides a method for stabilizing monothrombin in a thrombin-containing solution, wherein the thrombin content relative to all thrombin in the thrombin-containing solution is at least 70% or more. Is.
- [001 1] According to the present invention, it is possible to improve the storage stability and quality of a thrombin-containing solution by suppressing a decrease in the remaining ratio and activity of the thrombin in the thrombin-containing solution. Furthermore, the storage stability and quality of a liquid fibrinogen measurement reagent suitable for emergency testing can be improved.
- FIG. 1 is a 10-20% SDS-PAGE image of purified thrombin.
- the figure on the left is a purified thrombin, the figure on the right is a purified; S- and _thrombin mixture.
- A is equivalent to one thrombin and B is equivalent to S- and r-thrombin.
- FIG. 2 Survival rate of thrombin content after 37 ° C accelerated test. The clotting time at week 0 was set to 100%.
- FIG. 3 Thrombin activity after 3 7 ° C accelerated test. The clotting time at 0 week was set to 100%.
- FIG. 4 Delay of solidification time of sample 1 after 3 7 ° C accelerated test. The clotting time at week 0 was set to 100%.
- the content of one thrombin relative to the total thrombin in the thrombin-containing solution in the present invention is 70% or more, preferably 80% or more, more preferably 90% or more.
- the total thrombin content in the thrombin-containing solution is preferably 70% or more and S_ and / or r_thrombin content is less than 30%, and the thrombin content is 80% or more and S_ And / or ⁇ -thrombin content is more preferably less than 20%, one thrombin content is 90% or more and S_ and / or r_thrombin content is particularly preferably less than 10%.
- the present invention relates to total thrombin; as S_ and thrombin content increases; S- and r_ thrombin decrease the residual rate and activity of single thrombin in solution.
- S_ and thrombin content increases
- S- and r_ thrombin decrease the residual rate and activity of single thrombin in solution.
- the thrombin in the present invention refers to one containing one thrombin, and the total thrombin refers to all of one thrombin, ⁇ -thrombin and r_thrombin.
- the thrombin content relative to the total thrombin in the present invention is determined by measuring each of thrombin, 3-thrombin, and —thrombin by a known method capable of quantitatively measuring thrombin. It can be calculated by the following formula (1).
- One thrombin content of all thrombin (one thrombin measurement value / total thrombin measurement value) X 1 00 ⁇ ⁇ ⁇ Formula (1)
- an activity measurement method may be used, such as protein quantification by densitometry, and any measurement method may be used.
- one thrombin and its degradation product may be separated and purified by a known method.
- thrombin content is determined by an activity measurement method (synthetic substrate method) using a synthetic substrate S-2 2 3 8 (manufactured by Daiichi Chemicals), a known ion exchange resin is used. After fractionation of 3_ and r_thrombin, the degradation activity for S-2 2 3 8 of each fraction was measured, and the activity ratio (%) of hi-thrombin activity to total thrombin activity was determined. Can be sought.
- the protein content is divided into three _ and r-thrombin fractions using a known protein analysis electrophoresis, and the protein content is determined by densitometry. It can be determined as the ratio (%) of the protein content of thrombin to the protein content of thrombin.
- the thrombin used in the present invention may be derived from animals such as humans, prepared by genetic engineering techniques, or commercially available drugs.
- Examples of the method for preparing thrombin used in the present invention include known protein separation-purification methods such as filtration, washing, drying, recrystallization, various column chromatography, HPLC, and liquid-liquid partition. More specifically, an ion exchange resin such as a cation exchange resin, an affinity resin such as a benzamidine resin, a limiting filtration membrane, a gel filtration and the like can be mentioned.
- the thrombin-containing solution of the present invention is an aqueous solution in which thrombin is suspended or dissolved in water and / or an organic solvent, an organic solvent solution, or a mixed solution of water / organic solvent, preferably an aqueous solution or water / organic solvent. It is a mixed solution.
- the organic solvent has effects on fibrinogen measurement, such as the degradation of monothrombin and activity inhibition. If it does not do, it will not specifically limit, For example, dimethylsulfoxide, glycerol, polyethyleneglycol, polypropylene glycol etc. are mentioned. These can be used alone or in combination of two or more.
- thrombin degradation and activity inhibition it is preferably 4-9, more preferably 5.5-7, and even more preferably 6-6.5.
- a buffer having a buffer capacity in the range of pH 4 to 9 can be appropriately selected and used.
- citrate, phosphoric acid, acetic acid One type or two or more types can be appropriately combined from imidazole, HEP ES, MO PS, BIS—TRIS, TRIS, MO PSO, ADA, MES and the like.
- citrate, phosphate, imidazole, BI S_T RIS, MO P SO, ADA , MES etc. can be used in combination of one or more.
- the amount of these buffering agents to be added is not particularly limited as long as it has a buffering capacity.
- the concentration of the buffering agent in the thrombin-containing solution is preferably 5 to 1,000 mM, particularly 20 to 30 OmM.
- the activity amount of monothrombin in the thrombin-containing solution of the present invention is not particularly limited as long as it is adjusted to the target activity value according to the monothrombin content relative to the total thrombin.
- the activity of thrombin is 20 to 1,000 units / mL, more preferably 50 to 500 units / mL, particularly 100 to 30 by a known synthetic substrate method. It is preferably 0 unit / mL.
- the thrombin-containing solution of the present invention can be produced by a known production method by appropriately blending the following known compounds within a range not affecting fibrinogen measurement.
- the thrombin-containing solution has a concentration that does not affect fibrinogen measurement.
- a known compound used for stabilizing thrombin and improving storage stability may be appropriately blended, and examples thereof include calcium ions, organic acids, surfactants and proteins.
- the calcium ions are preferably water-soluble calcium compounds such as calcium chloride, calcium lactate, calcium gluconate, calcium glucuronate, and calcium tartrate. These calcium compounds can be used alone or in combination of two or more.
- the stabilizing effective amount of the calcium compound with respect to monothromthrombin is not particularly limited as long as it is an amount that improves stability.
- the concentration of calcium in the thrombin-containing solution is preferably 5 mM to 1 O OmM. And more preferably 10 mM to 50 mM.
- organic acid examples include formic acid, acetic acid, propionic acid, butyric acid, valeric acid, oxalic acid, malonic acid, succinic acid, gluconic acid, lactic acid, glucuronic acid, glycolic acid, tartaric acid, malic acid, Examples include citrate, glutaric acid, aminoacetic acid, aminocabronic acid, and any of the free acid and its salt may be used. These organic acids can be used alone or in combination of two or more.
- the amount of the organic acid added is not particularly limited as long as it is an amount that improves the stability of the thrombin-containing solution.
- the concentration of the organic acid in the thrombin-containing solution is preferably 10 mM to 50 OmM. More preferably 50 mM to 200 mM.
- the surfactant may be any of an anionic surfactant, a cationic surfactant, an amphoteric surfactant, and a nonionic surfactant. Specific examples thereof include: The following are listed.
- anionic surfactant examples include sodium dodecyl sulfate, sodium dodecyl sulfonate, sodium dodecyl-N-sarcosinate, sodium cholate, sodium deoxycholate, and sodium taurodeoxycholate.
- cationic surfactant examples include cetyltrimethyl ammonium chloride, tetradecyl ammonium bromide, dodecyl pyridinium chloride and the like.
- amphoteric surfactants examples include 3 _ [(3-Colamidpropyl) dimethylammonio] _1_Propanesulfonic acid (CHAPS), 3-[(3-Colamidpropyl) dimethylammonio] _2-2-hydroxy. 1_propanesulfonic acid (CHAP SO), palmitoyl lysolecithin, dodecyl N-betaine, dodecyl 1; S-alanine and the like.
- Nonionic surfactants include, for example, octyl glucoside, peptyl thioglucoside, decanol 1 N-methyl glucamide, polyoxyethylene dodecyl ether, polyoxyethylene heptamethyl hexyl ether, polyoxyethylene isooctyl ⁇ Nyl ether (Triton (registered trademark) X series), polyoxyethylene nonylphenyl ether, polyoxyethylene fatty acid ester, sucrose fatty acid ester, polyoxyethylene sorbitol ester (Tween (registered trademark) series), etc. Is mentioned. Of these surfactants, nonionic surfactants are particularly preferably used. These surfactants can be used alone or in combination of two or more.
- the amount of the surfactant added is not particularly limited as long as it is an amount that improves the stability of the ⁇ _thrombin-containing solution.
- the concentration of the surfactant in the one thrombin-containing solution is preferably It is 0.001 to 1 w / V%, and more preferably 0.005 to 0.1 w / v%.
- protein examples include albumin, gelatin, globulin and the like. These proteins can be used alone or in combination of two or more.
- the amount of the protein added is not particularly limited as long as it is an amount that improves the stability of the solution containing the monothrombin.
- the concentration of the protein in the solution containing the monothrombin is preferably 0.05 to 1 0 w / v% More preferably, it is 0.1-5 w / v%.
- the monothrombin-containing solution of the present invention may contain, in addition to the above, a high molecular polysaccharide and / or synthetic polymer in a range that does not affect fibrinogen measurement in order to improve measurement reproducibility. Good.
- polymer polysaccharide examples include dextran 40 and dextran 7
- polymeric polysaccharides can be used alone or in combination of two or more.
- the amount of the polymeric polysaccharide added is not particularly limited as long as it is an amount that improves reproducibility.
- the concentration of the polymeric polysaccharide in the thrombin-containing solution is preferably 0.1 to 1 Ow / v. %, More preferably 0.3-3 w / v%
- synthetic polymers include polyvinyl alcohol 500, polyvinyl alcohol 1 500, polyvinyl alcohol 2000, polyethylene glycol 1 500, polyethylene glycol 2000, polyethylene glycol 4000, polyethylene glycol 6000, Examples include polyethylene glycol 8000, polyethylene glycol 20000, and polyvinylpyrrolidone. These synthetic polymers can be used alone or in combination of two or more.
- the amount of the synthetic polymer added is not particularly limited as long as it is an amount that improves reproducibility.
- the concentration of the synthetic polymer in the thrombin-containing solution is 0.1 to 1 Ow / v%. Preferably, it is 0.3 to 3 w / v%.
- an appropriate preservative may be added to the thrombin-containing solution of the present invention as long as it does not affect fibrinogen measurement.
- the preservative include sodium azide, Procrine (registered trademark) 300, ciprofloxacin, propionic acid or sodium benzoate, and one or a combination of two or more of these may be used. Can do. If necessary, add salts such as sodium chloride and general stabilizers such as amino acids and sugars. Rushito
- the amount of the preservative added is not particularly limited as long as it is within a predetermined range.
- the concentration of Procrine (registered trademark) 300 in the thrombin-containing solution is 0.001 to “! W / v%, Preferably, the concentration is 0.0 1 to 0.1 w / v%
- the concentration described above is the concentration when the commercially available Procrine (registered trademark) 300 is 1 O Ow / v%. Yes.
- the liquid fibrinogen measurement reagent of the present invention contains the above-mentioned solution of thrombin and may contain a compound that is usually used for measuring fibrinogen within a range that does not affect fibrinogen measurement.
- the liquid fibrinogen measurement reagent can be used as a coagulation ability test reagent, particularly a fibrinogen quantitative reagent. Specifically, after diluting the fibrinogen standard solution with the sample dilution buffer to the prescribed concentration, add the diluted fibrinogen standard solution and the liquid fibrinogen measurement reagent, and measure the clotting time at 37 ° C. A calibration curve can be created based on the measured fibrinogen concentration and clotting time, and the clotting time measured value of the test sample can be converted from the calibration curve to determine the fibrinogen concentration in the test sample.
- liquid fibrinogen measurement reagent containing the thrombin-containing solution of the present invention can measure the activity of a thrombin activity inhibitory substance, such as antithrombin activity, hirudin activity, and chemical synthesis inhibitor activity.
- a thrombin activity inhibitory substance such as antithrombin activity, hirudin activity, and chemical synthesis inhibitor activity.
- liquid fibrinogen measurement reagent of the present invention may be a measurement reagent kit, and in such a case, may include a sample dilution buffer for diluting the sample and the standard solution. .
- Sample dilution buffers include MES, Bis-Tris, ADA, PIP ES, AC ES, MO P SO, B ES, MO PS, T ES, HEP ES, DIP SO, TA P SO, PO P SO HEPP SO, EPPS, Tricine, Bicine, TAPS, CHES, CAPSO, CAPS and other good buffer solutions and barbital buffer solutions.
- the buffer for dilution of the sample is added to the thrombin-containing solution
- the thrombin-containing solution It may be used so that it is in the range of PH and concentration.
- thrombin solution of each fraction was adsorbed onto B enz am idin eS epharose (2.1 x 6 cm, Pharmacia), washed with the same buffer containing 0.5 M NaCI, and then 0.1 MB enz am idine 0. 5M
- Purified monothrombin and purified S 2 -thrombin were separated by 10_20% S DS_polyacrylamide gel electrophoresis (S DS-PAGE) under non-reduction according to the Laemm II method. After protein staining with CBB, the color was sufficiently decolored, and the degree of staining (Int ns si ty) of each band was measured with a densitometer (Kodak IS 440 CF).
- the purity of purified one thrombin is about 95% (about 5% includes s- and r_thrombin) and purified; the purity of s ⁇ r-thrombin was about 80% (about 20% contains one thrombin).
- A is equivalent to one thrombin, B is; one corresponding to S one and ⁇ -thrombin.
- Thrombin-containing solution is 100 units / 1_ 1 thrombin, 15 OmM sodium chloride, 0.05% Procrine (registered trademark) 300, ⁇ ⁇ —Thrombin is contained at the activity ratio described below
- a solution of pH 6.3 consisting of 5 OmM ME S buffer, prepared using purified one thrombin and purified ⁇ -thrombin.
- Condition 1 Total thrombin activity; S ⁇ : r_thrombin activity ratio: 5%
- the residual rate of the thrombin content was measured when the thrombin-containing solutions of conditions 1 to 5 were stored at 37 ° C for 0, 1, 2 weeks. In addition, the measurement of the content of hi-thrombin was performed by the purity test of Production Example 2.
- a solution containing thrombin with an activity ratio of 20% S s r-thrombin coexists with a thrombin content remaining rate of 81% when stored at 37 ° C for 2 weeks; S ⁇ : The smaller the amount of ⁇ -thrombin (ie, the higher the activity ratio of thrombin), the higher the residual rate of thrombin.
- thrombin for total thrombin activity Activity ratio of 70%
- survival rate of the thrombin content after storage at 37 ° C for 2 weeks is expected to be 70% or more.
- it carries one thrombin content with respect to the total thrombin thrombin-containing solution is 70% or more, preferably 800/0 or more, and more preferably it can be seen that at 90 ⁇ 1 ⁇ 2 or more.
- the total thrombin content of the thrombin-containing solution is 70% or more; and S_ and / or _thrombin content is more preferably less than 30%, and the thrombin content is 80% or more and S_ and It can be seen that the content of / or r_thrombin is more preferably less than 20%, the content of one thrombin is 90% or more and the content of S_ and / or _thrombin is particularly preferably less than 10%.
- Example 1 For the one thrombin-containing solution prepared in Example 2 under the conditions 1-5, the thrombin-containing solution stored at 37 ° C for 0, 1, 2 weeks was used to measure the clotting time of human plasma (sample 1 and sample 2). Measurements were made. In this experiment, 50 L of each thrombin-containing solution was added to 100 L of plasma diluted 10-fold with a sample diluent (TC buffer, Sysmex), and coagulated with Coagrex 800 (Sysmex). Time was measured.
- TC buffer, Sysmex a sample diluent
- Sysmex coagulated with Coagrex 800
- condition 5 in the thrombin-containing solution with ⁇ ⁇ r-thrombin activity ratio of 50% (condition 5), the initial coagulation time after storage for 2 weeks at 37 ° C Relative to 0 / o of 1 was over 20%, but the solution with ⁇ ⁇ r-thrombin activity ratio of 20% or less (condition 1_4) was less than 110%
- the thrombin-containing solution of the present invention is stable in the solution and useful as a liquid fibrinogen measurement reagent.
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES07849800T ES2382758T3 (es) | 2006-12-21 | 2007-12-06 | Procedimiento para estabilizar la alfa-trombina en solución que contiene trombina |
EP07849800A EP2096440B1 (en) | 2006-12-21 | 2007-12-06 | Method for stabilizing alpha-thrombin in thrombin-containing solution |
US12/519,191 US8580532B2 (en) | 2006-12-21 | 2007-12-06 | Method for stabilizing α-thrombin in thrombin-containing solution |
JP2008550039A JP5121725B2 (ja) | 2006-12-21 | 2007-12-06 | トロンビン含有溶液中のα−トロンビンの安定化方法 |
CN200780046549.2A CN101558310B (zh) | 2006-12-21 | 2007-12-06 | 含凝血酶的溶液中的α-凝血酶的稳定化方法 |
AT07849800T ATE554397T1 (de) | 2006-12-21 | 2007-12-06 | Verfahren zur stabilisierung von alpha-thrombin in einer thrombinhaltigen lösung |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006344121 | 2006-12-21 | ||
JP2006-344121 | 2006-12-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008075455A1 true WO2008075455A1 (ja) | 2008-06-26 |
Family
ID=39536094
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2007/001367 WO2008075455A1 (ja) | 2006-12-21 | 2007-12-06 | トロンビン含有溶液中のα-トロンビンの安定化方法 |
Country Status (7)
Country | Link |
---|---|
US (1) | US8580532B2 (ja) |
EP (1) | EP2096440B1 (ja) |
JP (1) | JP5121725B2 (ja) |
CN (1) | CN101558310B (ja) |
AT (1) | ATE554397T1 (ja) |
ES (1) | ES2382758T3 (ja) |
WO (1) | WO2008075455A1 (ja) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3242656A4 (en) * | 2015-01-06 | 2018-08-29 | St. Teresa Medical, Inc. | Hemostatic products |
EP3280444A4 (en) * | 2015-04-10 | 2019-03-27 | Adimab, LLC | METHOD FOR CLEANING HETERODIMEROUS MULTISPECIFIC ANTIBODIES FROM PARENTAL HOMODIMERIC ANTIBODY TYPES |
US10828387B2 (en) | 2015-11-12 | 2020-11-10 | St. Teresa Medical, Inc. | Method of sealing a durotomy |
CN106337044B (zh) * | 2016-09-30 | 2018-08-31 | 迈克生物股份有限公司 | 凝血酶溶液 |
CN106350499B (zh) * | 2016-09-30 | 2018-07-10 | 迈克生物股份有限公司 | 凝血酶溶液的稳定剂 |
CN106480007B (zh) * | 2016-09-30 | 2018-02-23 | 迈克生物股份有限公司 | 凝血酶溶液的稳定剂 |
CN106350500B (zh) * | 2016-09-30 | 2018-02-23 | 迈克生物股份有限公司 | 凝血酶溶液 |
CN106350501B (zh) * | 2016-09-30 | 2018-06-01 | 迈克生物股份有限公司 | 凝血酶溶液的稳定剂 |
JP6889535B2 (ja) * | 2016-10-05 | 2021-06-18 | デンカ株式会社 | 赤血球の凝集方法及び分離方法並びに赤血球凝集用試薬 |
CN107942063A (zh) * | 2016-10-13 | 2018-04-20 | 北京众驰伟业科技发展有限公司 | 一种血浆纤维蛋白原的检测试剂、其检测方法及应用 |
CN106645751B (zh) * | 2016-12-27 | 2018-08-03 | 北京赛科希德科技股份有限公司 | 一种纤维蛋白原含量检测试剂盒 |
US10953128B2 (en) | 2017-11-02 | 2021-03-23 | St. Teresa Medical, Inc. | Fibrin sealant products |
CN112578130A (zh) * | 2019-09-30 | 2021-03-30 | 积水医疗科技(苏州)有限公司 | 凝血酶溶液、试剂盒、凝血酶的稳定化方法、检测试剂以及凝血酶时间的测定方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62106028A (ja) | 1985-10-28 | 1987-05-16 | ワ−ナ−−ランバ−ト・コンパニ− | トロンビン製剤 |
JPS6440433A (en) | 1987-08-05 | 1989-02-10 | Green Cross Corp | Aqueous liquid composition of thrombin |
EP1136084A1 (de) * | 2000-03-18 | 2001-09-26 | Aventis Behring GmbH | Thrombin-Zubereitungen und Verfahren zu ihrer Herstellung |
JP2004191367A (ja) | 2002-11-28 | 2004-07-08 | Sysmex Corp | トロンビン試薬及び検査試薬キット |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU7320300A (en) | 1999-09-27 | 2001-04-30 | International Reagents Corporation | Means of stabilizing thrombin and compositions |
EP2167041B1 (en) * | 2007-06-15 | 2012-11-07 | Zymogenetics, Inc. | Stabilized thrombin compositions |
US20090101809A1 (en) * | 2007-09-05 | 2009-04-23 | Zymogenetics, Inc. | Mass spectrometry-based quantitative assay for determining abundance of molecular species in a composition |
-
2007
- 2007-12-06 ES ES07849800T patent/ES2382758T3/es active Active
- 2007-12-06 US US12/519,191 patent/US8580532B2/en active Active
- 2007-12-06 WO PCT/JP2007/001367 patent/WO2008075455A1/ja active Application Filing
- 2007-12-06 JP JP2008550039A patent/JP5121725B2/ja active Active
- 2007-12-06 EP EP07849800A patent/EP2096440B1/en active Active
- 2007-12-06 CN CN200780046549.2A patent/CN101558310B/zh active Active
- 2007-12-06 AT AT07849800T patent/ATE554397T1/de active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62106028A (ja) | 1985-10-28 | 1987-05-16 | ワ−ナ−−ランバ−ト・コンパニ− | トロンビン製剤 |
JPS6440433A (en) | 1987-08-05 | 1989-02-10 | Green Cross Corp | Aqueous liquid composition of thrombin |
EP1136084A1 (de) * | 2000-03-18 | 2001-09-26 | Aventis Behring GmbH | Thrombin-Zubereitungen und Verfahren zu ihrer Herstellung |
JP2004191367A (ja) | 2002-11-28 | 2004-07-08 | Sysmex Corp | トロンビン試薬及び検査試薬キット |
Non-Patent Citations (4)
Title |
---|
BOISSEL J.P. ET AL.: "COVALENT STRUCTURE OF BETA AND GAMMA AUTOLYTIC DERIVATIVES OF HUMAN ALPHA-THROMBIN", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 259, no. 9, 1984, pages 5691 - 5697, XP008109259 * |
CHANG J.Y.: "THE STRUCTURES AND PROTEOLLYTIC SPECIFICITIES OF AUTOLYSED HUMAN", BIOCHEM. J., vol. 240, 1986, pages 797 - 802, XP008109238 * |
FENTON J.W. ET AL.: "HUMAN THROMBINS. PRODUCTION, EVALUATION, AND PROPERTIES OF ALPHA-THROMBIN", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 252, no. 11, 1977, pages 3587 - 3598, XP009010724 * |
KARLSSON G.: "ANALYSIS OF HUMAN ALPHA-THROMBIN BY HYDROPHOBIC INTERACTION HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY", PROTEIN EXPRESSION AND PURIFICATION, vol. 27, 2003, pages 171 - 174, XP002502252 * |
Also Published As
Publication number | Publication date |
---|---|
JPWO2008075455A1 (ja) | 2010-04-08 |
ATE554397T1 (de) | 2012-05-15 |
ES2382758T3 (es) | 2012-06-13 |
US8580532B2 (en) | 2013-11-12 |
US20100047834A1 (en) | 2010-02-25 |
EP2096440A1 (en) | 2009-09-02 |
JP5121725B2 (ja) | 2013-01-16 |
CN101558310A (zh) | 2009-10-14 |
EP2096440B1 (en) | 2012-04-18 |
EP2096440A4 (en) | 2010-03-24 |
CN101558310B (zh) | 2013-05-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008075455A1 (ja) | トロンビン含有溶液中のα-トロンビンの安定化方法 | |
Mares et al. | Specific adsorption of some complement activation proteins to polysulfone dialysis membranes during hemodialysis | |
US20060246052A1 (en) | Means for stabilization of thrombin and compositions | |
BRPI0707268A2 (pt) | purificação e uso de um fator para ajudar a cura de ferimento | |
JPH0694726A (ja) | 血液凝固第xiii因子活性測定方法および該測定用試薬キット | |
EP3483603A1 (en) | Hemoglobin liquid preparation and liquid chromatography method for measuring hemoglobin component | |
JP3348228B2 (ja) | トロンボプラスチン試薬を製造するための改良された抽出方法 | |
EP0123883B1 (de) | Verfahren zur fotometrischen Bestimmung der aktivierten partiellen Thromboplastinzeit und Reagenz dazu | |
JP2004191367A (ja) | トロンビン試薬及び検査試薬キット | |
JP2002526557A (ja) | トロンボプラスチン試薬ならびにそのような試薬の製造および使用方法 | |
AU2016224834B2 (en) | Method for purifying and quantifying thrombin and its degradation polypeptides | |
JP3939771B2 (ja) | 血液凝固性の測定用診断試験のための添加剤 | |
EP0906340B1 (de) | Reinigung von faktor viii-komplex durch immunaffinitätschromatographie | |
EP3018481A1 (en) | Blood coagulation time prolonging agent | |
CA2287129C (en) | Stabilization of biological fluids by addition of sterol esters | |
KR100707119B1 (ko) | 안정화된 안티트롬빈 iii 제제 | |
EP0570356A1 (de) | Reagens zur Bestimmung der aktivierten partiellen Thromboplastinzeit (aPTT) | |
US20020151646A1 (en) | Thromboplastin reagent and method for manufacturing the same | |
van der Giesen et al. | Consequences of the N B transition of albumin for the binding of warfarin in human serum | |
CN109444439A (zh) | 一种稳定的液体型凝血酶时间测定试剂盒 | |
JP4060123B2 (ja) | タンパク質の失活を抑制する方法 | |
CN110997933A (zh) | 用于稳定无细胞核酸和细胞的方法和组合物 | |
Weerasinghe et al. | A rapid method for the isolation of coagulation factor XII from human plasma | |
CN117129687A (zh) | 一种粪便保存液及其制备方法 | |
CA2428508A1 (en) | Control and calibration material for blood coagulation tests |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780046549.2 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07849800 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008550039 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007849800 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12519191 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |